Trodelvy PopPK
Indication: Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Population PK simulator for sacituzumab govitecan (SG, Trodelvy) — TROP2-directed ADC for TNBC, HR+/HER2- breast cancer, and urothelial cancer. Triple-analyte model: intact ADC, free SN-38 payload (with UGT1A1 genotype covariate), and total antibody with time-dependent clearance. Based on Sathe et al. Clin Pharmacokinet 2024.
Drug Overview
Clinical Context
- Molecular Target
- TROP2
- Drug Class
- Antibody-Drug Conjugate (ADC)
- Therapeutic Area
- Oncology
- Indication
- Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
- Route of Administration
- IV Infusion
Model Information
- Model Type
- Population PK (Triple-analyte: ADC + SN-38 payload + total antibody)
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Trodelvy allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK (Triple-analyte: ADC + SN-38 payload + total antibody) model characterizes the pharmacokinetics of this antibody-drug conjugate (adc) following iv infusion administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Trodelvy PK simulator?
This is a free, interactive pharmacokinetic simulator for Trodelvy used in Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Trodelvy belong to?
Trodelvy is classified as a Antibody-Drug Conjugate (ADC) that targets TROP2. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV Infusion administration of Trodelvy. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK (Triple-analyte: ADC + SN-38 payload + total antibody) model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
PopPK of Docetaxel
Mirvetuximab Soravtansine (ELAHERE) PopPK
FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload
Patritumab Deruxtecan (HER3-DXd) PopPK
EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload
capecitabine
PBPK-PD of ADCs
Datroway PopPK
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Ready to Simulate?
Launch the Trodelvy simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community